Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03449524 · ClinicalTrials.gov registry record · Phase 2
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
A Phase 2 study, sponsored by Complexa.
- Terminated
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT03449524 is a Phase 2 study that was terminated before completion, run by Complexa. The registered enrollment target is 69 participants.
The verdict
NCT03449524, a Phase 2 study, was terminated before completion, sponsored by Complexa.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH.
Interventions
- OTHER Placebo
- DRUG 75mg CXA-10
- DRUG 150mg CXA-10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2020-08-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03449524
The ClinicalTrials.gov registry entry for NCT03449524 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Complexa, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03449524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03449524 about?
NCT03449524 is a clinical study titled "PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)". This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH.
What is the current status of trial NCT03449524?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2018-08-01. Estimated completion is 2020-08-05.
What interventions are being tested in trial NCT03449524?
The interventions under investigation include: Placebo (OTHER), 75mg CXA-10 (DRUG), 150mg CXA-10 (DRUG).
Who is sponsoring clinical trial NCT03449524?
This trial is sponsored by Complexa, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.